Retinal Imaging Techniques for Neurodegenerative Diseases: Parkinson's Disease and Beyond

Abstract

Given that the retina shares embryonic origin with the central nervous system, past evidence has attempted to prove parallel pathology of neurovegetative diseases in the retina. Retinal imaging techniques provide in vivo structural and functional data with advantages of high resolution and low cost in a noninvasive way. In recent literature, the retina presents significant alterations related to Parkinson's disease (PD) and other neurodegenerative diseases through multimodal retinal images due to its neural accessibility. However, current findings remain fragmented and inconsistent causing the existing reviews limited in a certain modality or incomplete without mention of interdisciplinary integration. The purpose of this paper is to systematically review and synthesize the application of retinal imaging techniques in PD and other neurodegenerative diseases. We begin with the connections between the retina and the brain and the main retinal imaging modalities. We then summarize the retinal changes in patients with PD and other neurodegenerative diseases during the past decade. Additionally, we discuss the application of artificial intelligence in PD prediction and retinal probe. By integrating histopathological insights with advanced imaging analytics, we highlight retinal changes as biomarkers for neurodegeneration, which accelerate their clinical translation for early diagnosis and monitoring of PD in the future. and other neurodegenerative diseases.

Keywords

artificial intelligence / neurodegenerative diseases / optical coherence tomography / optical coherence tomography angiography / Parkinson's disease / retinal changes

References

[1] O. B. Tysnes and A. Storstein, “Epidemiology of Parkinson's Disease,” Journal of Neural Transmission 124, no. 8 (2017): 901–905.

[2] D. Aarsland, L. Batzu, G. M. Halliday, et al., “Parkinson Disease-Associated Cognitive Impairment,” Nature Reviews Disease Primers 7, no. 1 (2021): 47.

[3] A. Verstraeten, J. Theuns, and C. Van Broeckhoven, “Progress in Unraveling the Genetic Etiology of Parkinson Disease in a Genomic Era,” Trends in Genetics 31, no. 3 (2015): 140–149.

[4] R. Balestrino and A. H. V. Schapira, “Parkinson Disease,” European Journal of Neurology 27, no. 1 (2020): 27–42.

[5] E. R. Dorsey and B. R. Bloem, “The Parkinson Pandemic-A Call to Action,” JAMA Neurology 75, no. 1 (2018): 9–10.

[6] J. Zhu, Y. Cui, J. Zhang, et al., “Temporal Trends in the Prevalence of Parkinson's Disease From 1980 to 2023: A Systematic Review and Meta-Analysis,” Lancet Healthy Longevity 5, no. 7 (2024): e464–e479.

[7] D. Su, Y. Cui, C. He, et al., “Projections for Prevalence of Parkinson's Disease and Its Driving Factors in 195 Countries and Territories to 2050: Modelling Study of Global Burden of Disease Study 2021,” BMJ 388 (2025): e080952.

[8] K. R. Chaudhuri, J. P. Azulay, P. Odin, et al., “Economic Burden of Parkinson's Disease: A Multinational, Real-World, Cost-of-Illness Study,” Drugs—Real World Outcomes 11, no. 1 (2024): 1–11.

[9] Y. Qiu, T. Jin, E. Mason, and M. C. W. Campbell, “Predicting Thioflavin Fluorescence of Retinal Amyloid Deposits Associated With Alzheimer's Disease From Their Polarimetric Properties,” Translational Vision Science & Technology 9, no. 2 (2020): 47.

[10] T. G. Beach, J. Carew, G. Serrano, et al., “Phosphorylated α-Synuclein-immunoreactive Retinal Neuronal Elements in Parkinson's Disease Subjects,” Neuroscience Letters 571 (2014): 34–38.

[11] A. London, I. Benhar, and M. Schwartz, “The Retina as a Window to the Brain-From Eye Research to CNS Disorders,” Nature Reviews Neurology 9, no. 1 (2013): 44–53.

[12] S. S. Hayreh, “The 1994 Von Sallman Lecture. The Optic Nerve Head Circulation in Health and Disease,” Experimental Eye Research 61, no. 3 (1995): 259–272.

[13] H. Kolb, E. Fernandez, and R. Nelson, eds., Webvision: The Organization of the Retina and Visual System (University of Utah Health Sciences Cente, Webvision, 1995).

[14] Y. Koronyo, D. Biggs, E. Barron, et al., “Retinal Amyloid Pathology and Proof-of-Concept Imaging Trial in Alzheimer's Disease,” JCI Insight 2, no. 16 (2017): e93621.

[15] M. Koronyo-Hamaoui, Y. Koronyo, A. V. Ljubimov, et al., “Identification of Amyloid Plaques in Retinas From Alzheimer's Patients and Noninvasive In Vivo Optical Imaging of Retinal Plaques in a Mouse Model,” supplement, NeuroImage 54, no. Suppl 1 (2011): S204–S217.

[16] S. D. Walter, H. Ishikawa, K. M. Galetta, et al., “Ganglion Cell Loss in Relation to Visual Disability in Multiple Sclerosis,” Ophthalmology 119, no. 6 (2012): 1250–1257.

[17] M. You, R. Rong, Z. Zeng, X. Xia, and D. Ji, “Transneuronal Degeneration in the Brain During Glaucoma,” Frontiers in Aging Neuroscience 13 (2021): 643685.

[18] M. Lawlor, H. Danesh-Meyer, L. A. Levin, I. Davagnanam, E. De Vita, and G. T. Plant, “Glaucoma and the Brain: Trans-Synaptic Degeneration, Structural Change, and Implications for Neuroprotection,” Survey of Ophthalmology 63, no. 3 (2018): 296–306.

[19] M. Entezari, S. Azhari, and A. Ramezani, “Fundus Findings in Spontaneous Subarachnoid Hemorrhage and Their Correlation With Neurologic Characteristics,” European Journal of Ophthalmology 19, no. 3 (2009): 460–465.

[20] D. Wang, Y. Li, C. Wang, et al., “Localized Retinal Nerve Fiber Layer Defects and Stroke,” Stroke 45, no. 6 (2014): 1651–1656.

[21] S. Chiquita, A. C. Rodrigues-Neves, F. I. Baptista, et al., “The Retina as a Window or Mirror of the Brain Changes Detected in Alzheimer's Disease: Critical Aspects to Unravel,” Molecular Neurobiology 56, no. 8 (2019): 5416–5435.

[22] L. Guo, E. M. Normando, P. A. Shah, L. De Groef, and M. F. Cordeiro, “Oculo-Visual Abnormalities in Parkinson's Disease: Possible Value as Biomarkers,” Movement Disorders 33, no. 9 (2018): 1390–1406.

[23] A. G. Hamedani and A. W. Willis, “Self-Reported Visual Dysfunction in Parkinson Disease: The Survey of Health, Ageing and Retirement in Europe,” European Journal of Neurology 27, no. 3 (2020): 484–489.

[24] C. D. J. M. Borm, F. Visser, M. Werkmann, et al., “Seeing Ophthalmologic Problems in Parkinson Disease: Results of a Visual Impairment Questionnaire,” Neurology 94, no. 14 (2020): e1539–e1547.

[25] L. Veys, M. Vandenabeele, I. Ortuño-Lizarán, et al., “Retinal α-Synuclein Deposits in Parkinson's Disease Patients and Animal Models,” Acta Neuropathologica 137, no. 3 (2019): 379–395.

[26] R. Del Pino, M. Acera, A. Murueta-Goyena, et al., “Visual Dysfunction Is Associated With Cognitive Impairment in Parkinson's Disease,” Parkinsonism & Related Disorders 92 (2021): 22–25.

[27] M. Ptito, M. Bleau, and J. Bouskila, “The Retina: A Window Into the Brain,” Cells 10, no. 12 (2021): 3269.

[28] A. Kurita, H. Koshikawa, T. Akiba, K. Seki, H. Ishikawa, and M. Suzuki, “Visual Hallucinations and Impaired Conscious Visual Perception in Parkinson Disease,” Journal of Geriatric Psychiatry and Neurology 33, no. 6 (2020): 377–385.

[29] M. Pengo, A. Murueta-Goyena, S. Teijeira-Portas, et al., “Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson's Disease,” Journal of Parkinson's Disease 12, no. 5 (2022): 1633–1643.

[30] L. A. Yannuzzi, M. D. Ober, J. S. Slakter, et al., “Ophthalmic Fundus Imaging: Today and Beyond,” American Journal of Ophthalmology 137, no. 3 (2004): 511–524.

[31] N. Panwar, P. Huang, J. Lee, et al., “Fundus Photography in the 21st Century—A Review of Recent Technological Advances and Their Implications for Worldwide Healthcare,” Telemedicine and e-Health 22, no. 3 (2016): 198–208.

[32] S. Miri, S. Glazman, L. Mylin, and I. Bodis-Wollner, “A Combination of Retinal Morphology and Visual Electrophysiology Testing Increases Diagnostic Yield in Parkinson's Disease,” Parkinsonism & Related Disorders 22, no. Suppl 1 (2016): S134–S137.

[33] Y. He, A. Carass, Y. Liu, et al., “Structured Layer Surface Segmentation for Retina OCT Using Fully Convolutional Regression Networks,” Medical Image Analysis 68 (2021): 101856.

[34] M. Pircher and R. J. Zawadzki, “Review of Adaptive Optics OCT (AO-OCT): Principles and Applications for Retinal Imaging [Invited],” Biomedical Optics Express 8, no. 5 (2017): 2536–2562.

[35] R. Told, L. Ginner, A. Hecht, et al., “Comparative Study Between a Spectral Domain and a High-Speed Single-Beam Swept Source OCTA System for Identifying Choroidal Neovascularization in AMD,” Scientific Reports 6 (2016): 38132.

[36] T. Simpson and D. Fonn, “Optical Coherence Tomography of the Anterior Segment,” Ocular Surface 6, no. 3 (2008): 117–127.

[37] A. Murueta-Goyena, R. Del Pino, M. Galdós, et al., “Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease,” Annals of Neurology 89, no. 1 (2021): 165–176.

[38] I. Laíns, J. C. Wang, Y. Cui, et al., “Retinal Applications of Swept Source Optical Coherence Tomography (OCT) and Optical Coherence Tomography Angiography (OCTA),” Progress in Retinal and Eye Research 84 (2021): 100951.

[39] R. Mastropasqua, F. Evangelista, F. Amodei, et al., “Optical Coherence Tomography Angiography in Macular Neovascularization: A Comparison Between Different OCTA Devices,” Translational Vision Science & Technology 9, no. 11 (2020): 6.

[40] R. F. Spaide, J. M. Klancnik,, M. J. Cooney, et al., “Volume-Rendering Optical Coherence Tomography Angiography of Macular Telangiectasia Type 2,” Ophthalmology 122, no. 11 (2015): 2261–2269.

[41] B. E. O'Bryhim, R. S. Apte, N. Kung, D. Coble, and G. P. Van Stavern, “Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings,” JAMA Ophthalmology 136, no. 11 (2018): 1242–1248.

[42] J. A. van de Kreeke, H. T. Nguyen, E. Konijnenberg, et al., “Optical Coherence Tomography Angiography in Preclinical Alzheimer's Disease,” British Journal of Ophthalmology 104, no. 2 (2020): 157–161.

[43] H. M. Snyder, R. A. Corriveau, S. Craft, et al., “Vascular Contributions to Cognitive Impairment and Dementia Including Alzheimer's Disease,” Alzheimer's & Dementia 11, no. 6 (2015): 710–717.

[44] L. Huang, D. Zhang, J. Ji, Y. Wang, and R. Zhang, “Central Retina Changes in Parkinson's Disease: A Systematic Review and Meta-Analysis,” Journal of Neurology 268, no. 12 (2021): 4646–4654.

[45] K. Golnik, “Nonglaucomatous Optic Atrophy,” Neurologic Clinics 28, no. 3 (2010): 631–640.

[46] S. Gibbon, D. P. Breen, and T. J. MacGillivray, “Optic Disc Pallor in Parkinson's Disease: A UK Biobank Study,” Movement Disorders 40, no. 6 (2025): 1123–1133.

[47] J. Y. Lee, A. Martin-Bastida, A. Murueta-Goyena, et al., “Multimodal Brain and Retinal Imaging of Dopaminergic Degeneration in Parkinson Disease,” Nature Reviews Neurology 18, no. 4 (2022): 203–220.

[48] C. D. J. M. Borm, M. Werkmann, D. de Graaf, et al., “Undetected Ophthalmological Disorders in Parkinson's Disease,” Journal of Neurology 269, no. 7 (2022): 3821–3832.

[49] N. K. Archibald, M. P. Clarke, U. P. Mosimann, and D. J. Burn, “Retinal Thickness in Parkinson's Disease,” Parkinsonism & Related Disorders 17, no. 6 (2011): 431–436.

[50] M. M. Moschos, G. Tagaris, L. Markopoulos, et al., “Morphologic Changes and Functional Retinal Impairment in Patients With Parkinson Disease Without Visual Loss,” European Journal of Ophthalmology 21, no. 1 (2011): 24–29.

[51] C. La Morgia, P. Barboni, G. Rizzo, et al., “Loss of Temporal Retinal Nerve Fibers in Parkinson Disease: A Mitochondrial Pattern?,” European Journal of Neurology 20, no. 1 (2013): 198–201.

[52] S. Kirbas, K. Turkyilmaz, A. Tufekci, and M. Durmus, “Retinal Nerve Fiber Layer Thickness in Parkinson Disease,” Journal of Neuro-Ophthalmology 33, no. 1 (2013): 62–65.

[53] C. R. Adam, E. Shrier, Y. Ding, S. Glazman, and I. Bodis-Wollner, “Correlation of Inner Retinal Thickness Evaluated by Spectral-Domain Optical Coherence Tomography and Contrast Sensitivity in Parkinson Disease,” Journal of Neuro-Ophthalmology 33, no. 2 (2013): 137–142.

[54] E. Garcia-Martin, J. M. Larrosa, V. Polo, et al., “Distribution of Retinal Layer Atrophy in Patients With Parkinson Disease and Association With Disease Severity and Duration,” American Journal of Ophthalmology 157, no. 2 (2014): 470–478.e2.

[55] M. Satue, M. Seral, S. Otin, et al., “Retinal Thinning and Correlation With Functional Disability in Patients With Parkinson's Disease,” British Journal of Ophthalmology 98, no. 3 (2014): 350–355.

[56] E. Garcia-Martin, D. Rodriguez-Mena, M. Satue, et al., “Electrophysiology and Optical Coherence Tomography to Evaluate Parkinson Disease Severity,” Investigative Opthalmology & Visual Science 55, no. 2 (2014): 696–705.

[57] E. S. Sari, R. Koc, A. Yazici, G. Sahin, and S. S. Ermis, “Ganglion Cell-Inner Plexiform Layer Thickness in Patients With Parkinson Disease and Association With Disease Severity and Duration,” Journal of Neuro-Ophthalmology 35, no. 2 (2015): 117–121.

[58] J. Chorostecki, N. Seraji-Bozorgzad, A. Shah, et al., “Characterization of Retinal Architecture in Parkinson's Disease,” Journal of the Neurological Sciences 355, no. 1–2 (2015): 44–48.

[59] A. Pilat, R. J. McLean, F. A. Proudlock, et al., “In Vivo Morphology of the Optic Nerve and Retina in Patients With Parkinson's Disease,” Investigative Opthalmology & Visual Science 57, no. 10 (2016): 4420–4427.

[60] M. Satue, J. Obis, R. Alarcia, et al., “Retinal and Choroidal Changes in Patients With Parkinson's Disease Detected by Swept-Source Optical Coherence Tomography,” Current Eye Research 43, no. 1 (2018): 109–115.

[61] M. M. Moschos and I. P. Chatziralli, “Evaluation of Choroidal and Retinal Thickness Changes in Parkinson's Disease Using Spectral Domain Optical Coherence Tomography,” Seminars in Ophthalmology 33, no. 4 (2018): 494–497.

[62] M. Unlu, D. Gulmez Sevim, M. Gultekin, and C. Karaca, “Correlations Among Multifocal Electroretinography and Optical Coherence Tomography Findings in Patients With Parkinson's Disease,” Neurological Science 39, no. 3 (2018): 533–541.

[63] S. Hasanov, E. Demirkilinc Biler, A. Acarer, C. Akkın, Z. Colakoglu, and O. Uretmen, “Functional and Morphological Assessment of Ocular Structures and Follow-Up of Patients With Early-Stage Parkinson's Disease,” International Ophthalmology 39, no. 6 (2019): 1255–1262.

[64] F. Visser, V. I. Apostolov, A. M. M. Vlaar, J. W. R. Twisk, H. C. Weinstein, and H. W. Berendse, “Visual Hallucinations in Parkinson's Disease Are Associated With Thinning of the Inner Retina,” Scientific Reports 10, no. 1 (2020): 21110.

[65] D. Bayram, G. Yüksel, T. Bayram, and H. Tireli, “Optical Coherence Tomography Findings in Parkinson's and Alzheimer's Disease—Retinal Changes in Neurodegenerative Disease,” Noro Psikiyatri Arsivi 58, no. 2 (2021): 103–107.

[66] J. Zhang, Y. Cao, K. Li, et al., “Correlations Between Retinal Nerve Fiber Layer Thickness and Cognitive Progression in Parkinson's Disease: A Longitudinal Study,” Parkinsonism & Related Disorders 82 (2021): 92–97.

[67] C. Rascunà, C. E. Cicero, C. G. Chisari, et al., “Retinal Thickness and Microvascular Pathway in Idiopathic Rapid Eye Movement Sleep Behaviour Disorder and Parkinson's Disease,” Parkinsonism & Related Disorders 88 (2021): 40–45.

[68] M. Atum and B. E. Demiryürek, “Retinal Morphological Changes During the Two Years of Follow-Up in Parkinson's Disease,” Ideggyógyászati szemle 74, no. 1–2 (2021): 57–63.

[69] Y. Zhao, W. Dai, and D. Liu, “Quantitative Analysis of Related Parameters of Retinal Nerve Fiber Layer and Ganglion Cell Complex Thickness in Patients With Different Degrees of Parkinson's Disease,” Aging Clinical and Experimental Research 34, no. 10 (2022): 2355–2361.

[70] Y. Kamata, N. Hara, T. Satou, T. Niida, and K. Mukuno, “Investigation of the Pathophysiology of the Retina and Choroid in Parkinson's Disease by Optical Coherence Tomography,” International Ophthalmology 42, no. 5 (2022): 1437–1445.

[71] S. Verghese, S. T. Berkowitz, V. M. Shah, et al., “Assessment of Retinal Manifestations of Parkinson's Disease Using Spectral Domain Optical Coherence Tomography: A Study in Indian Eyes,” Indian Journal of Ophthalmology 70, no. 2 (2022): 448–452.

[72] M. Tu, S. Yang, L. Zeng, Y. Tan, and X. Wang, “Retinal Vessel Density and Retinal Nerve Fiber Layer Thickness: A Prospective Study of One-Year Follow-Up of Patients With Parkinson's Disease,” International Journal of General Medicine 16 (2023): 3701–3712.

[73] M. Satue, L. Castro, E. Vilades, et al., “Ability of Swept-Source OCT and OCT-Angiography to Detect Neuroretinal and Vasculature Changes in Patients With Parkinson Disease and Essential Tremor,” Eye 37, no. 7 (2023): 1314–1319.

[74] L. Zhang, C. Zhuang, Y. Wang, H. Wang, G. Cui, and J. Guo, “Clinical Observation of Macular Superficial Capillary Plexus and Ganglion Cell Complex in Patients With Parkinson's Disease,” Ophthalmic Research 66, no. 1 (2023): 1181–1190.

[75] R. Elanwar, H. Al Masry, A. Ibrahim, M. Hussein, S. Ibrahim, and M. M. Masoud, “Retinal Functional and Structural Changes in Patients With Parkinson's Disease,” BMC Neurology 23, no. 1 (2023): 330.

[76] A. Chrysou, T. Heikka, S. van der Zee, J. M. Boertien, N. M. Jansonius, and T. van Laar, “Reduced Thickness of the Retina in De Novo Parkinson's Disease Shows A Distinct Pattern, Different From Glaucoma,” Journal of Parkinson's Disease 14, no. 3 (2024): 507–519.

[77] S. Poveda, X. Arellano, O. Bernal-Pacheco, and A. Valencia López, “Structural Changes in the Retina as a Potential Biomarker in Parkinson's Disease: An Approach From Optical Coherence Tomography,” Frontiers in Neuroimaging 3 (2024): 1340754.

[78] A. Murueta-Goyena, D. Romero-Bascones, S. Teijeira-Portas, et al., “Association of Retinal Neurodegeneration With the Progression of Cognitive Decline in Parkinson's Disease,” NPJ Parkinson's Disease 10, no. 1 (2024): 26.

[79] K. K. N. Tran, P. Y. Lee, D. I. Finkelstein, et al., “Altered Outer Retinal Structure, Electrophysiology and Visual Perception in Parkinson's Disease,” Journal of Parkinson's Disease 14, no. 1 (2024): 167–180.

[80] A. Murueta-Goyena, S. Teijeira-Portas, E. Blanco Martín, et al., “Dynamics of Retinal Changes in Early-Stage Parkinson's Disease,” Acta Neuropathologica Communications 13, no. 1 (2025): 20.

[81] J. Yu, Y. Feng, Y. Xiang, et al., “Retinal Nerve Fiber Layer Thickness Changes in Parkinson Disease: A Meta-Analysis,” PLoS One 9, no. 1 (2014): e85718.

[82] R. Inzelberg, J. A. Ramirez, P. Nisipeanu, and A. Ophir, “Retinal Nerve Fiber Layer Thinning in Parkinson Disease,” Vision Research 44, no. 24 (2004): 2793–2797.

[83] E. Garcia-Martin, L. E. Pablo, M. P. Bambo, et al., “Comparison of Peripapillary Choroidal Thickness Between Healthy Subjects and Patients With Parkinson's Disease,” PLoS One 12, no. 5 (2017): e0177163.

[84] L. Huang, C. Wang, W. Wang, Y. Wang, and R. Zhang, “The Specific Pattern of Retinal Nerve Fiber Layer Thinning in Parkinson's Disease: A Systematic Review and Meta-Analysis,” Journal of Neurology 268, no. 11 (2021): 4023–4032.

[85] V. Carelli, C. La Morgia, M. L. Valentino, P. Barboni, F. N. Ross-Cisneros, and A. A. Sadun, “Retinal Ganglion Cell Neurodegeneration in Mitochondrial Inherited Disorders,” Biochimica et Biophysica Acta (BBA)—Bioenergetics 1787, no. 5 (2009): 518–528.

[86] U. Mutlu, J. M. Colijn, M. A. Ikram, et al., “Association of Retinal Neurodegeneration on Optical Coherence Tomography With Dementia: A Population-Based Study,” JAMA Neurology 75, no. 10 (2018): 1256–1263.

[87] B. O. Gunay and N. C. Usta, “Retinal Pigment Epithelial Changes in Parkinson's Disease: A Spectral Domain Optical Coherence Tomography Study,” Photodiagnosis and Photodynamic Therapy 41 (2023): 103213.

[88] M. Ming, X. Li, X. Fan, et al., “Retinal Pigment Epithelial Cells Secrete Neurotrophic Factors and Synthesize Dopamine: Possible Contribution to Therapeutic Effects of RPE Cell Transplantation in Parkinson's Disease,” Journal of Translational Medicine 7 (2009): 53.

[89] I. Bodis-Wollner, P. B. Kozlowski, S. Glazman, and S. Miri, “α-Synuclein in the Inner Retina in Parkinson Disease,” Annals of Neurology 75, no. 6 (2014): 964–966.

[90] I. Ortuño-Lizarán, T. G. Beach, G. E. Serrano, D. G. Walker, C. H. Adler, and N. Cuenca, “Phosphorylated α-Synuclein in the Retina Is a Biomarker of Parkinson's Disease Pathology Severity,” Movement Disorders 33, no. 8 (2018): 1315–1324.

[91] D. L. Price, E. Rockenstein, M. Mante, et al., “Longitudinal Live Imaging of Retinal α-Synuclein::GFP Deposits in a Transgenic Mouse Model of Parkinson's Disease/Dementia With Lewy Bodies,” Scientific Reports 6 (2016): 29523.

[92] I. Ortuño-Lizarán, X. Sánchez-Sáez, P. Lax, et al., “Dopaminergic Retinal Cell Loss and Visual Dysfunction in Parkinson Disease,” Annals of Neurology 88, no. 5 (2020): 893–906.

[93] J. Esteve-Rudd, L. Fernández-Sánchez, P. Lax, E. De Juan, J. Martín-Nieto, and N. Cuenca, “Rotenone Induces Degeneration of Photoreceptors and Impairs the Dopaminergic System in the Rat Retina,” Neurobiology of Disease 44, no. 1 (2011): 102–115.

[94] T. Alasil, K. Wang, P. A. Keane, et al., “Analysis of Normal Retinal Nerve Fiber Layer Thickness by Age, Sex, and Race Using Spectral Domain Optical Coherence Tomography,” Journal of Glaucoma 22, no. 7 (2013): 532–541.

[95] H. M. Öhnell, A. Heijl, and B. Bengtsson, “Ageing and Glaucoma Progression of the Retinal Nerve Fibre Layer Using Spectral-Domain Optical Coherence Tomography Analysis,” Acta Ophthalmologica 99, no. 3 (2021): 260–268.

[96] B. V. Zlokovic, “Neurovascular Pathways to Neurodegeneration in Alzheimer's Disease and Other Disorders,” Nature Reviews Neuroscience 12, no. 12 (2011): 723–738.

[97] S. Guo and E. H. Lo, “Dysfunctional Cell-Cell Signaling in the Neurovascular Unit as a Paradigm for Central Nervous System Disease,” Stroke 40, no. 3 Suppl. (2009): S4–S7.

[98] C. Zhang, B. Wu, X. Wang, et al., “Vascular, Flow and Perfusion Abnormalities in Parkinson's Disease,” Parkinsonism & Related Disorders 73 (2020): 8–13.

[99] M. Marnane and G. Y. R. Hsiung, “Could Better Phenotyping Small Vessel Disease Provide New Insights Into Alzheimer Disease and Improve Clinical Trial Outcomes?,” Current Alzheimer Research 13, no. 7 (2016): 750–763.

[100] W. R. Kwapong, H. Ye, C. Peng, et al., “Retinal Microvascular Impairment in the Early Stages of Parkinson's Disease,” Investigative Opthalmology & Visual Science 59, no. 10 (2018): 4115–4122.

[101] J. Zou, K. Liu, F. Li, Y. Xu, L. Shen, and H. Xu, “Combination of Optical Coherence Tomography (OCT) and OCT Angiography Increases Diagnostic Efficacy of Parkinson's Disease,” Quantitative Imaging in Medicine and Surgery 10, no. 10 (2020): 1930–1939.

[102] C. Shi, Y. Chen, W. R. Kwapong, et al., “Characterization by Fractal Dimension Analysis of the Retinal Capillary Network in Parkinson Disease,” Retina 40, no. 8 (2020): 1483–1491.

[103] M. Zhou, L. Wu, Q. Hu, et al., “Visual Impairments Are Associated With Retinal Microvascular Density in Patients With Parkinson's Disease,” Frontiers in Neuroscience 15 (2021): 718820.

[104] A. Murueta-Goyena, M. Barrenechea, A. Erramuzpe, et al., “Foveal Remodeling of Retinal Microvasculature in Parkinson's Disease,” Frontiers in Neuroscience 15 (2021): 708700.

[105] Y. Zhang, D. Zhang, Y. Gao, et al., “Retinal Flow Density Changes in Early-Stage Parkinson's Disease Investigated by Swept-Source Optical Coherence Tomography Angiography,” Current Eye Research 46, no. 12 (2021): 1886–1891.

[106] C. B. Robbins, A. C. Thompson, P. K. Bhullar, et al., “Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease,” JAMA Ophthalmology 139, no. 2 (2021): 182–188.

[107] Y. Li, X. Wang, Y. Zhang, et al., “Retinal Microvascular Impairment in Parkinson's Disease With Cognitive Dysfunction,” Parkinsonism & Related Disorders 98 (2022): 27–31.

[108] B. Xu, X. Wang, J. Guo, et al., “Retinal Microvascular Density Was Associated With the Clinical Progression of Parkinson's Disease,” Frontiers in Aging Neuroscience 14 (2022): 818597.

[109] E. E. Christou, S. Konitsiotis, K. Pamporis, et al., “Inner Retinal Layers' Alterations of the Microvasculature in Early Stages of Parkinson's Disease: A Cross Sectional Study,” International Ophthalmology 43, no. 7 (2023): 2533–2543.

[110] T. Y. Yang, L. Q. Xie, Y. Zhang, et al., “Quantitative Study of Peripapillary Retinal Nerve Fiber Layer Thickness and Peripapillary Vessel Density in Patients With Different Stages of Parkinson's Disease,” International Journal of Ophthalmology 16, no. 5 (2023): 762–769.

[111] J. H. Ahn, M. C. Kang, D. Lee, J. W. Cho, K. A. Park, and J. Youn, “Central Retinal Microvasculature Damage Is Associated With Orthostatic Hypotension in Parkinson's Disease,” NPJ Parkinson's Disease 9, no. 1 (2023): 36.

[112] A. Kundu, J. P. Ma, C. B. Robbins, et al., “Longitudinal Analysis of Retinal Microvascular and Choroidal Imaging Parameters in Parkinson's Disease Compared With Controls,” Ophthalmology Science 3, no. 4 (2023): 100393.

[113] I. Giachos, A. Tsiogka, K. Manoli, et al., “Retinal Capillary Plexus in Parkinson's Disease Using Optical Coherence Tomography Angiography,” International Journal of Ophthalmology 17, no. 1 (2024): 131–136.

[114] R. Kromer, C. Buhmann, U. Hidding, et al., “Evaluation of Retinal Vessel Morphology in Patients With Parkinson's Disease Using Optical Coherence Tomography,” PLoS One 11, no. 8 (2016): e0161136.

[115] D. Gulmez Sevim, M. Unlu, S. Sonmez, M. Gultekin, C. Karaca, and A. Ozturk Oner, “Retinal Vessel Diameter Obtained by Optical Coherence Tomography Is Spared in Parkinson's Disease,” International Ophthalmology 39, no. 4 (2019): 813–819.

[116] Y. Zhang, Y. Li, C. Lai, et al., “Interocular Asymmetry of Retinal Change in Parkinson's Disease,” Parkinsonism & Related Disorders 125 (2024): 107037.

[117] C. W. Lin, T. T. Lai, S. J. Chen, and C. H. Lin, “Elevated α-Synuclein and NfL Levels in Tear Fluids and Decreased Retinal Microvascular Densities in Patients With Parkinson's Disease,” GeroScience 44, no. 3 (2022): 1551–1562.

[118] P. Scheltens, B. De Strooper, M. Kivipelto, et al., “Alzheimer's Disease,” Lancet 397, no. 10284 (2021): 1577–1590.

[119] S. Tiwari, V. Atluri, A. Kaushik, A. Yndart, and M. Nair, “Alzheimer's Disease: Pathogenesis, Diagnostics, and Therapeutics,” International Journal of Nanomedicine 14 (2019): 5541–5554.

[120] Y. Chen, M. Al-Nusaif, S. Li, et al., “Progress on Early Diagnosing Alzheimer's Disease,” Frontiers of Medicine 18, no. 3 (2024): 446–464.

[121] A. Grimaldi, N. Pediconi, F. Oieni, et al., “Neuroinflammatory Processes, A1 Astrocyte Activation and Protein Aggregation in the Retina of Alzheimer's Disease Patients, Possible Biomarkers for Early Diagnosis,” Frontiers in Neuroscience 13 (2019): 925.

[122] K. J. Cao, J. H. Kim, H. Kroeger, et al., “ARCAM-1 Facilitates Fluorescence Detection of Amyloid-Containing Deposits in the Retina,” Translational Vision Science & Technology 10, no. 7 (2021): 5.

[123] Y. Koronyo, A. Rentsendorj, N. Mirzaei, et al., “Retinal Pathological Features and Proteome Signatures of Alzheimer's Disease,” Acta Neuropathologica 145, no. 4 (2023): 409–438.

[124] S. Sen, R. Saxena, D. Vibha, et al., “Detection of Structural and Electrical Disturbances in Macula and Optic Nerve in Alzheimer's Patients and Their Correlation With Disease Severity,” Seminars in Ophthalmology 35, no. 2 (2020): 116–125.

[125] V. Cipollini, S. Abdolrahimzadeh, F. Troili, et al., “Neurocognitive Assessment and Retinal Thickness Alterations in Alzheimer Disease: Is There a Correlation?,” Journal of Neuro-Ophthalmology 40, no. 3 (2020): 370–377.

[126] P. Jindahra, N. Hengsiri, P. Witoonpanich, et al., “Evaluation of Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness in Alzheimer's Disease Using Optical Coherence Tomography,” Clinical Ophthalmology 14 (2020): 2995–3000.

[127] M. Marquié, S. Valero, M. Castilla-Marti, et al., “Association Between Retinal Thickness and β-Amyloid Brain Accumulation in Individuals With Subjective Cognitive Decline: Fundació ACE Healthy Brain Initiative,” Alzheimer's Research & Therapy 12, no. 1 (2020): 37.

[128] D. Sánchez, M. Castilla-Marti, M. Marquié, et al., “Evaluation of Macular Thickness and Volume Tested by Optical Coherence Tomography as Biomarkers for Alzheimer's Disease in a Memory Clinic,” Scientific Reports 10, no. 1 (2020): 1580.

[129] X. Mei, C. Qiu, Q. Zhou, et al., “Changes in Retinal Multilayer Thickness and Vascular Network of Patients With Alzheimer's Disease,” Biomedical Engineering Online 20, no. 1 (2021): 97.

[130] Z. B. Li, N. Li, H. Yu, Y. L. Wu, and X. Shen, “Evaluation of Retinal and Choroidal Changes in Patients With Alzheimer's Type Dementia Using Optical Coherence Tomography Angiography,” International Journal of Ophthalmology 14, no. 6 (2021): 860–868.

[131] J. Y. Shin, E. Y. Choi, M. Kim, H. K. Lee, and S. H. Byeon, “Changes in Retinal Microvasculature and Retinal Layer Thickness in Association With Apolipoprotein E Genotype in Alzheimer's Disease,” Scientific Reports 11, no. 1 (2021): 1847.

[132] C. Chiara, C. Gilda, M. Daniela, et al., “A Two-Year Longitudinal Study of Retinal Vascular Impairment in Patients With Amnestic Mild Cognitive Impairment,” Frontiers in Aging Neuroscience 14 (2022): 993621.

[133] Z. Farzinvash, M. Abutorabi-Zarchi, M. Manaviat, and H. Zare Mehrjerdi, “Retinal Ganglion Cell Complex in Alzheimer Disease: Comparing Ganglion Cell Complex and Central Macular Thickness in Alzheimer Disease and Healthy Subjects Using Spectral Domain-Optical Coherence Tomography,” Basic and Clinical Neuroscience Journal 13, no. 5 (2022): 675–684.

[134] J. Chua, C. Li, L. K. H. Ho, et al., “A Multi-Regression Framework to Improve Diagnostic Ability of Optical Coherence Tomography Retinal Biomarkers to Discriminate Mild Cognitive Impairment and Alzheimer's Disease,” Alzheimer's Research & Therapy 14, no. 1 (2022): 41.

[135] G. Campbell and D. Mahad, “Neurodegeneration in Progressive Multiple Sclerosis,” Cold Spring Harbor Perspectives in Medicine 8, no. 10 (2018): a028985.

[136] J. E. Galvin, M. J. Kleiman, and M. Walker, “Using Optical Coherence Tomography to Screen for Cognitive Impairment and Dementia,” Journal of Alzheimer's Disease 84, no. 2 (2021): 723–736.

[137] Z. Hu, L. Wang, D. Zhu, et al., “Retinal Alterations as Potential Biomarkers of Structural Brain Changes in Alzheimer's Disease Spectrum Patients,” Brain Sciences 13, no. 3 (2023): 460.

[138] X. Ma, Z. Xie, H. Wang, et al., “A Cross-Sectional Study of Retinal Vessel Changes Based on Optical Coherence Tomography Angiography in Alzheimer's Disease and Mild Cognitive Impairment,” Frontiers in Aging Neuroscience 15 (2023): 1101950.

[139] J. A. Cipolla, H. Jiang, A. G. Y. Simms, B. Baumel, T. Rundek, and J. Wang, “Impaired Retinal Capillary Function in Patients With Alzheimer Disease,” Journal of Neuro-Ophthalmology 44, no. 1 (2024): 30–34.

[140] G. Ashraf, M. McGuinness, M. A. Khan, C. Obtinalla, X. Hadoux, and P. van Wijngaarden, “Retinal Imaging Biomarkers of Alzheimer's Disease: A Systematic Review and Meta-Analysis of Studies Using Brain Amyloid Beta Status for Case Definition,” Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 15, no. 2 (2023): e12421.

[141] Y. Rotenstreich, I. Sharvit-Ginon, I. Sher, et al., “Thicker Macula in Asymptomatic APOE Ɛ4 Middle-Aged Adults at High AD Risk,” Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 14, no. 1 (2022): e12275.

[142] P. J. Snyder, L. N. Johnson, Y. Y. Lim, et al., “Nonvascular Retinal Imaging Markers of Preclinical Alzheimer's Disease,” Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 4 (2016): 169–178.

[143] J. Girbardt, T. Luck, J. Kynast, et al., “Reading Cognition From the Eyes: Association of Retinal Nerve Fibre Layer Thickness With Cognitive Performance in a Population-Based Study,” Brain Communications 3, no. 4 (2021): fcab258.

[144] F. C. T. van der Heide, A. Khawaja, T. T. J. M. Berendschot, et al., “Associations of Inner Retinal Layers With Risk of Incident Dementia: An Individual Participant Data Analysis of Four Prospective Cohort Studies,” Alzheimer's & Dementia 20, no. 1 (2024): 211–220.

[145] N. El-Darzi, N. Mast, D. A. Buchner, et al., “Low-Dose Anti-HIV Drug Efavirenz Mitigates Retinal Vascular Lesions in a Mouse Model of Alzheimer's Disease,” Frontiers in Pharmacology 13 (2022): 902254.

[146] O. M. Rifai, S. McGrory, C. B. Robbins, et al., “The Application of Optical Coherence Tomography Angiography in Alzheimer's Disease: A Systematic Review,” Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 13, no. 1 (2021): e12149.

[147] J. Chua, Q. Hu, M. Ke, et al., “Retinal Microvasculature Dysfunction Is Associated With Alzheimer's Disease and Mild Cognitive Impairment,” Alzheimer's Research & Therapy 12, no. 1 (2020): 161.

[148] E. Arthur, S. Ravichandran, P. J. Snyder, et al., “Retinal Mid-Peripheral Capillary Free Zones Are Enlarged in Cognitively Unimpaired Older Adults at High Risk for Alzheimer's Disease,” Alzheimer's Research & Therapy 15, no. 1 (2023): 172.

[149] S. Asanad, M. Fantini, W. Sultan, et al., “Retinal Nerve Fiber Layer Thickness Predicts CSF Amyloid/Tau Before Cognitive Decline,” PLoS One 15, no. 5 (2020): e0232785.

[150] P. Chaitanuwong, S. Jariyakosol, S. Apinyawasisuk, et al., “Changes in Ocular Biomarkers From Normal Cognitive Aging to Alzheimer's Disease: A Pilot Study,” Eye and Brain 15 (2023): 15–23.

[151] R. Dobson and G. Giovannoni, “Multiple Sclerosis—A Review,” European Journal of Neurology 26, no. 1 (2019): 27–40.

[152] S. L. Costa, K. Pandey, J. Hrdina, M. Rondon, and H. Devos, “Vision Problems in Multiple Sclerosis,” Archives of Physical Medicine and Rehabilitation 101, no. 12 (2020): 2263–2265.

[153] M. Ilardi, R. Nolan-Kenney, G. Fatterpekar, et al., “Role for OCT in Detecting Hemi-Macular Ganglion Cell Layer Thinning in Patients With Multiple Sclerosis and Related Demyelinating Diseases,” Journal of the Neurological Sciences 419 (2020): 117159.

[154] H. Yilmaz, A. Ersoy, and E. Icel, “Assessments of Vessel Density and Foveal Avascular Zone Metrics in Multiple Sclerosis: An Optical Coherence Tomography Angiography Study,” Eye 34, no. 4 (2020): 771–778.

[155] B. Cordon, E. Vilades, E. Orduna, et al., “Angiography With Optical Coherence Tomography as a Biomarker in Multiple Sclerosis,” PLoS One 15, no. 12 (2020): e0243236.

[156] H. Jiang, G. R. Gameiro, Y. Liu, et al., “Visual Function and Disability Are Associated With Increased Retinal Volumetric Vessel Density in Patients With Multiple Sclerosis,” American Journal of Ophthalmology 213 (2020): 34–45.

[157] O. C. Murphy, O. Kwakyi, M. Iftikhar, et al., “Alterations in the Retinal Vasculature Occur in Multiple Sclerosis and Exhibit Novel Correlations With Disability and Visual Function Measures,” Multiple Sclerosis Journal 26, no. 7 (2020): 815–828.

[158] F. Paul, P. A. Calabresi, F. Barkhof, et al., “Optical Coherence Tomography in Multiple Sclerosis: A 3-year Prospective Multicenter Study,” Annals of Clinical and Translational Neurology 8, no. 12 (2021): 2235–2251.

[159] A. Balıkçı, N. Parmak Yener, and M. Seferoğlu, “Optical Coherence Tomography and Optical Coherence Tomography Angiography Findings in Multiple Sclerosis Patients,” Neuro-Ophthalmology 46, no. 1 (2022): 19–33.

[160] S. A. Khader, A. E. Nawar, A. A. Ghali, and A. M. Ghoneim, “Evaluation of Optical Coherence Tomography Angiography Findings in Patients With Multiple Sclerosis,” Indian Journal of Ophthalmology 69, no. 6 (2021): 1457–1463.

[161] D. Montorio, R. Lanzillo, A. Carotenuto, et al., “Retinal and Choriocapillary Vascular Changes in Early Stages of Multiple Sclerosis: A Prospective Study,” Journal of Clinical Medicine 10, no. 24 (2021): 5756.

[162] S. Ava, Y. Tamam, L. Hazar, et al., “Relationship Between Optical Coherence Tomography Angiography and Visual Evoked Potential in Patients With Multiple Sclerosis,” Indian Journal of Ophthalmology 70, no. 3 (2022): 873–878.

[163] M. Bostan, J. Chua, Y. C. Sim, et al., “Microvascular Changes in the Macular and Parafoveal Areas of Multiple Sclerosis Patients Without Optic Neuritis,” Scientific Reports 12, no. 1 (2022): 13366.

[164] A. Najafi, N. Ashoori, K. Hosseini, and V. Abbasi, “Optical Coherence Tomography in Multiple Sclerosis,” Medical Hypothesis, Discovery and Innovation in Ophthalmology 12, no. 4 (2024): 187–193.

[165] S. Mrabet, Y. Falfoul, M. Bouassida, et al., “Retinal Changes in Multiple Sclerosis: An Optical Coherence Tomography and Angiography Study,” Revue Neurologique 180, no. 7 (2024): 622–631.

[166] M. C. Savastano, V. Nociti, F. Giannuzzi, et al., “Optical Coherence Tomography Advanced Parameters in Patients With Multiple Sclerosis: Ophthalmological and Neurological Assessments,” American Journal of Ophthalmology 267 (2024): 41–49.

[167] A. U. Brandt, T. Oberwahrenbrock, M. Ringelstein, et al., “Primary Retinal Pathology in Multiple Sclerosis as Detected by Optical Coherence Tomography,” Brain 134, no. Pt 11 (2011): e193; author reply e194.

[168] A. Petzold, L. J. Balcer, P. A. Calabresi, et al., “Retinal Layer Segmentation in Multiple Sclerosis: A Systematic Review and Meta-Analysis,” Lancet Neurology 16, no. 10 (2017): 797–812.

[169] M. O. Ulusoy, B. Horasanlı, and S. Işık-Ulusoy, “Optical Coherence Tomography Angiography Findings of Multiple Sclerosis With or Without Optic Neuritis,” Neurological Research 42, no. 4 (2020): 319–326.

[170] G. Bsteh, H. Hegen, N. Krajnc, et al., “Retinal Thinning Differentiates Treatment Effects in Relapsing Multiple Sclerosis Below the Clinical Threshold,” Annals of Clinical and Translational Neurology 12, no. 2 (2025): 345–354.

[171] A. Abraham, N. L. Kavoussi, W. Sui, C. Bejan, J. A. Capra, and R. Hsi, “Machine Learning Prediction of Kidney Stone Composition Using Electronic Health Record-Derived Features,” Journal of Endourology 36, no. 2 (2022): 243–250.

[172] S. Sengupta, A. Singh, H. A. Leopold, T. Gulati, and V. Lakshminarayanan, “Ophthalmic Diagnosis Using Deep Learning With Fundus Images—A Critical Review,” Artificial Intelligence in Medicine 102 (2020): 101758.

[173] T. Cui, D. Lin, S. Yu, et al., “Deep Learning Performance of Ultra-Widefield Fundus Imaging for Screening Retinal Lesions in Rural Locales,” JAMA Ophthalmology 141, no. 11 (2023): 1045–1051.

[174] G. Pahuja and B. Prasad, “Deep Learning Architectures for Parkinson's Disease Detection by Using Multi-Modal Features,” Computers in Biology and Medicine 146 (2022): 105610.

[175] T. Welton, S. Hartono, W. Lee, et al., “Classification of Parkinson's Disease by Deep Learning on Midbrain MRI,” Frontiers in Aging Neuroscience 16 (2024): 1425095.

[176] A. Murueta-Goyena, R. Del Pino, P. Reyero, et al., “Parafoveal Thinning of Inner Retina Is Associated With Visual Dysfunction in Lewy Body Diseases,” Movement Disorders 34, no. 9 (2019): 1315–1324.

[177] L. Álvarez-Rodríguez, A. Pueyo, J. de Moura, et al., “Fully Automatic Deep Convolutional Approaches for the Screening of Neurodegeneratives Diseases Using Multi-View OCT Images,” Artificial Intelligence in Medicine 158 (2024): 103006.

[178] C. Tran, K. Shen, K. Liu, et al., “Deep Learning Predicts Prevalent and Incident Parkinson's Disease From UK Biobank Fundus Imaging,” Scientific Reports 14, no. 1 (2024): 3637.

[179] X. Liu, T. Fu, Z. Pan, et al., “Automated Layer Segmentation of Retinal Optical Coherence Tomography Images Using a Deep Feature Enhanced Structured Random Forests Classifier,” IEEE Journal of Biomedical and Health Informatics 23, no. 4 (2019): 1404–1416.

[180] S. Sotoudeh-Paima, A. Jodeiri, F. Hajizadeh, and H. Soltanian-Zadeh, “Multi-Scale Convolutional Neural Network for Automated AMD Classification Using Retinal OCT Images,” Computers in Biology and Medicine 144 (2022): 105368.

[181] Y. Zhou, M. A. Chia, S. K. Wagner, et al., “A Foundation Model for Generalizable Disease Detection From Retinal Images,” Nature 622, no. 7981 (2023): 156–163.

[182] A. Richardson, A. Kundu, R. Henao, et al., “Multimodal Retinal Imaging Classification for Parkinson's Disease Using a Convolutional Neural Network,” Translational Vision Science & Technology 13, no. 8 (2024): 23.

[183] J. Huang, X. Zhang, R. Jin, et al., “Wavelet-Based Selection-And-Recalibration Network for Parkinson's Disease Screening in OCT Images,” Computer Methods and Programs in Biomedicine 256 (2024): 108368.

[184] J. C. Vasquez-Correa, T. Arias-Vergara, J. R. Orozco-Arroyave, B. Eskofier, J. Klucken, and E. Noth, “Multimodal Assessment of Parkinson's Disease: A Deep Learning Approach,” IEEE Journal of Biomedical and Health Informatics 23, no. 4 (2019): 1618–1630.

[185] S. Ahn, J. Shin, S. J. Song, et al., “Neurologic Dysfunction Assessment in Parkinson Disease Based on Fundus Photographs Using Deep Learning,” JAMA Ophthalmology 141, no. 3 (2023): 234–240.

[186] P. Shah, D. Mishra, M. Shanmugam, M. J. Vighnesh, and H. Jayaraj, “Acceptability of Artificial Intelligence-Based Retina Screening in General Population,” Indian Journal of Ophthalmology 70, no. 4 (2022): 1140–1144.

[187] T. Yao, R. Wang, Y. Meng, and X. Hun, “Photoelectrochemical Sensing of α-Synuclein Based on a AuNPs/Graphdiyne-Modified Electrode Coupled With a Nanoprobe,” ACS Applied Materials & Interfaces 13, no. 22 (2021): 26515–26521.

[188] P. Gaur, M. Galkin, A. Kurochka, S. Ghosh, D. A. Yushchenko, and V. V. Shvadchak, “Fluorescent Probe for Selective Imaging of α-Synuclein Fibrils in Living Cells,” ACS Chemical Neuroscience 12, no. 8 (2021): 1293–1298.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).